Exiting Through Turbulence

Authored by Jacob Ambrose Willson, Senior Editor, Criticaleye

For several years, private equity ownership has appeared to be one of the most effective pathways to accelerated growth. This article by Criticaleye’s Jacob Ambrose Willson explores how the high interest rate environment is impacting PE-backed businesses gearing towards an exit.

Featuring commentary from:

Alastair Mills, Managing Director & Head of European Business Services, H.I.G. Capital
Nick Burns, CEO, Reward Gateway
Paul Lester, Chair, Essentra plc

Share this with your Community



Contributors
Alastair Mills
Managing Director & Head of European Business Services
H.I.G. European Capital Partners LLP
Nick Burns
CEO
Reward Gateway | Edenred
Paul Lester CBE
Non-executive Chair
McCarthy Stone


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Leadership in Times of Radical Change

There are significant changes underway in the UK’s water industry. Phil Aspin, CFO of United Utilities, talks to Criticaleye about adaptability, investment and his own personal journey as a finance leader. A...


Click here to download this insight

VIEWPOINTS | Top Trends in Private Equity Right Now

Higher financing costs, more challenging exit markets and a tougher macroeconomic backdrop are challenging some of the assumptions that have underpinned the traditional private equity playbook. As a result, em...


How to Execute a Successful Exit with Paul Lester CBE

A successful exit is rarely defined by valuation alone. Behind every strong outcome is strategic preparation, disciplined leadership and an organisation that is ready for transition. In this episode of Criticaley...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 176




Hitachi Solutions Stream NATS E.ON UK Legal & General Mayborn Group AlixPartners London Stock Exchange Group British Land Drax Group plc Rolls-Royce Lightsource bp Global Payments NatWest Group GlaxoSmithKline plc LACE Partners